PT  - JOURNAL ARTICLE
AU  - Ben Hamilton
AU  - Harry Green
AU  - Neel Heerasing
AU  - Peter Hendy
AU  - Lucy Moore
AU  - Neil Chanchlani
AU  - Gareth Walker
AU  - Claire Bewshea
AU  - Nicholas A Kennedy
AU  - Tariq Ahmad
AU  - James Goodhand
TI  - Incidence and prevalence of inflammatory bowel disease in Devon, UK
AID  - 10.1136/flgastro-2019-101369
DP  - 2021 Nov 01
TA  - Frontline Gastroenterology
PG  - 461--470
VI  - 12
IP  - 6
4099  - http://fg.bmj.com/content/12/6/461.short
4100  - http://fg.bmj.com/content/12/6/461.full
SO  - Frontline Gastroenterol2021 Nov 01; 12
AB  - Background and aims We sought to define temporal changes in prevalence of inflammatory bowel disease (IBD) in East Devon, UK, in order to facilitate service planning over the next 5 years.Methods Multiple primary and secondary care databases were used to identify and verify cases. Point prevalence and incidence of IBD were reported in April 2017 and from 2008 to 2016, respectively. Future prevalence and healthcare activity requirements were estimated by linear regression.Results Prevalence of ulcerative colitis (UC), Crohn’s disease (CD) and inflammatory bowel disease unclassified (IBDU) were 479.72, 265.94 and 35.34 per 100 000 persons, respectively. In 2016, the incidence rates of UC, CD and IBDU were 15.4, 10.7 and 1.4 per 100 000 persons per year, respectively. There were no significant changes in the incidence of CD (p=0.49, R=0.26) or UC (p=0.80, R=0.10). IBD prevalence has increased by 39.9% (95% CI 28.2 to 53.7) in the last 10 years without differences in the rate of change between UC and CD. Overall, 27% of patients were managed in primary care, a quarter of whom were eligible but not receiving endoscopic surveillance. Outpatient clinics, MRI and biologic use, but not helpline calls, admissions, or surgeries increased over and above the change in IBD prevalence.Conclusions We report one of the highest prevalence and incidence rates of IBD from Northern Europe. Overall, IBD incidence is static, but prevalence is increasing. We estimate that 1% of our population will live with IBD between 2025 and 2030.Data are available upon reasonable request. Data contain patient identifiable information and under GDPR must be stored deidentified where possible on secure NHS servers, and is not publicly available. Limited datasets may be shared to other NHS users when clinical justification is warranted.